Excellent long-term outcomes of patients with human epidermal growth factor receptor 2 (HER2) positive early breast cancer (EBC) treated with trastuzumab-based treatments have been reported [1,2,3,4,5]. This evidence concerns the gene ERBB2 and breast cancer.